---
title: "Therapy dose mediates the relationship between buprenorphine/naloxone and opioid treatment outcomes in youth receiving medication for opioid use disorder treatment"
collection: publications
permalink: /publication/2020-10-15-habib2020restriction
excerpt: 'This paper used data from the NIDA-CTN-0010 trial to evaluate the mediating effects of psychosocial treatment-related variables (therapy dose and therapeutic alliance) on end-of-treatment opioid abstinence in a sample of youth with Opioid Use Disorder. We found that participants in the Bup-Nal group attended more therapy sessions (16 vs 6 sessions), had increased therapeutic alliance at week-4, and had less opioid use by week-12 compared to those in the Detox group. In both treatment arms, youth who attended more therapy sessions were less likely to have a week-12 opioid positive urine. In a multiple mediator model, therapy dose mediated the association between treatment arm and opioid abstinence.'
venue: 'Journal of Addiction Medicine'
date: 2022-03-16
paperurl: 'https://pubmed.ncbi.nlm.nih.gov/33973923/'
citation: '<b>Kady, A.</b>,* Hammond, C. J.,* Park, G., Vidal, C., Wenzel, K., & Fishman, M. (2022). Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment. Journal of addiction medicine, 16(2), e97â€“e104. https://doi.org/10.1097/ADM.0000000000000861
<br><br> *equally contributing first authors'
---
This paper used data from the NIDA-CTN-0010 trial to evaluate the mediating effects of psychosocial treatment-related variables (therapy dose and therapeutic alliance) on end-of-treatment opioid abstinence in a sample of youth with Opioid Use Disorder. We found that participants in the Bup-Nal group attended more therapy sessions (16 vs 6 sessions), had increased therapeutic alliance at week-4, and had less opioid use by week-12 compared to those in the Detox group. In both treatment arms, youth who attended more therapy sessions were less likely to have a week-12 opioid positive urine. In a multiple mediator model, therapy dose mediated the association between treatment arm and opioid abstinence.
